News and Trends 4 Oct 2019
ADC Therapeutics Cancels Nasdaq IPO Amidst Market Growth Fears
The Swiss biotech ADC Therapeutics has withdrawn its application for a €182M ($200M) Nasdaq IPO, citing adverse market conditions caused by global manufacturing slowdowns. ADC Therapeutics declined to comment on…